We would like to share some information about the Rasilez/Tekturna ALTITUDE study. Since December 2011 Novartis has been in ongoing discussions with health authorities worldwide about the implications of the preliminary findings from ALTITUDE for Rasilez/Tekturna patients.
Throughout 2012, a number of health authorities issued statements responding to these findings or updating their recommendations to physicians and patients about the use of aliskiren products based on the interim analysis of ALTITUDE. Please check the local product labeling for further information.
Download the PDFs for frequently asked questions